Summary & Overview
CPT 3061F: Negative Microalbuminuria Test, Urine Screening
CPT code 3061F represents documentation of a negative microalbuminuria urine test, indicating no detectable albumin and suggesting the absence of kidney damage often linked to diabetes. This preventive and monitoring test is an important part of chronic disease management and early kidney disease surveillance, with implications for clinical follow-up and quality reporting nationally.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise examination of the clinical purpose of the code, typical sites of service, and the role of the documented negative result in care pathways. The publication outlines how 3061F is used in practice for monitoring at-risk patients, and summarizes common billing modifiers associated with the service where available.
The article provides practical benchmarks and contextual policy considerations for national audiences, including how the code supports quality measurement and chronic disease management workflows. Data not available in the input includes payer-specific coverage rules, associated ICD-10 diagnoses, and related procedure codes; where such details are absent, this report notes their unavailability and focuses on the clinical and billing context that is available.
Billing Code Overview
CPT code 3061F documents a negative microalbuminuria test, a urine test that measures the amount of albumin present. A negative result indicates no albumin detected in the urine, which suggests the absence of kidney damage commonly associated with diabetes. The documentation reflects that the provider reviewed and recorded the negative test result.
Service type: Laboratory test (urine microalbuminuria screening)
Typical site of service: Outpatient clinic, primary care office, or laboratory facility
Clinical & Coding Specifications
Clinical Context
A 54-year-old patient with type 2 diabetes presents for routine chronic disease monitoring. At the clinic visit the provider orders a urine microalbumin (albumin-to-creatinine ratio) to screen for early diabetic nephropathy. The sample is collected in the outpatient clinic laboratory or provided by the patient at a primary care or endocrinology visit. The laboratory performs the urine albumin measurement and reports a negative result (no albumin detected above the assay threshold). The provider reviews and documents the negative microalbuminuria test in the chart, reinforcing that there is no current evidence of albuminuria and that routine surveillance will continue. Typical site of service is outpatient clinic or outpatient laboratory; service type is diagnostic laboratory testing performed as part of chronic disease management. Common scenario modifiers include telehealth review of results (95) or point-of-care collection and testing (PO).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
95 | Synchronous telemedicine service rendered via real-time interactive audio and video | Use when results are reviewed and communicated to the patient during a telehealth encounter |